Dr. Ami V Desai
Claim this profileUniversity of Chicago Comprehensive Cancer Center
Expert in Neuroblastoma
Studies Cancer
22 reported clinical trials
45 drugs studied
About Ami V Desai
Education:
- Obtained MD from Robert Wood Johnson Medical School.
- Earned MSCE from the University of Pennsylvania.
Experience:
- Board-certified pediatrician specializing in pediatric hematology/oncology.
- Focus areas include solid tumors, sarcomas, neuroblastoma, and adolescent and young adult (AYA) cancer care.
- Research interests in pharmacology and developmental therapeutics for solid tumors.
- Lead investigator in multiple studies with publications in renowned journals.
- Practicing since 2013 and a member of several prestigious medical societies.
Area of expertise
1Neuroblastoma
Global LeaderMYC positive
Stage IV
MYC negative
2Cancer
Stage IV
SMARCB1 positive
FOXO1 fusion negative
Affiliated Hospitals
Clinical Trials Ami V Desai is currently running
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting1 award Phase 212 criteria
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
More about Ami V Desai
Clinical Trial Related4 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Ami V Desai has experience with
- Dinutuximab
- Cyclophosphamide
- Irinotecan
- Vincristine
- Temozolomide
- Dactinomycin
Breakdown of trials Ami V Desai has run
Neuroblastoma
Cancer
Parotid Gland Cancer
Tumors
Ganglioneuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Ami V Desai specialize in?
Is Ami V Desai currently recruiting for clinical trials?
Are there any treatments that Ami V Desai has studied deeply?
What is the best way to schedule an appointment with Ami V Desai?
What is the office address of Ami V Desai?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.